Dongcheng Pharmaceuticals: Technetium [99mTc] Tetrofosmin Injection included in the 2025 medical insurance catalogue.

Dongcheng Pharmaceuticals announced that its wholly-owned subsidiary Andike's technetium [99mTc] sestamibi injection has been included in the "National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List". This product is only used for diagnosis and can be used for myocardial perfusion imaging in drug loading and resting states. The product is classified as a Class B injection and is categorized as a diagnostic radiopharmaceutical for the cardiovascular system. The "Medical Insurance Catalog" will take effect on January 1, 2026 and will not have a significant impact on the company's business performance for the time being.